Christopher Jordan

Christopher Jordan joined Chimerix in 2022 as Vice President of Regulatory Affairs.  He has more than 30 years of global drug development experience spanning the development process from compound discovery to Phase 3, submission and approval.  Prior to joining Chimerix, Mr. Jordan served as the Vice President of Regulatory Affairs at Endocyte, and then as a Senior Global Program Regulatory Director following the acquisition by Novartis.  In these roles he led the development and execution of the global regulatory strategy for PLUVICTO®, the first radioligand therapy approved for metastatic castration resistant prostate cancer, and LOCAMETZ®, the first PET imaging agent approved to select patients for PLUVICTO therapy.  Prior to his roles at Endocyte/Novartis, Mr. Jordan worked at Eli Lilly in roles of increasing responsibility across discovery, project management, clinical research and regulatory affairs.  He also served as an adjunct professor of regulatory affairs at George Washington University from 2017 to 2019. Mr. Jordan earned his Master of Science in Health Science in Regulatory Affairs from George Washington University, and Bachelor Science in Chemistry from Purdue University.

Categorised in:

This post was written by Michelle LaSpaluto